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Background: To evaluate the therapeutic benefit of 3D-image-guided high-dose-rate intracavitary brachytherapy
(3D-image-guided HDR-BT) used as a salvage treatment of intensity modulated radiation therapy (IMRT) in patients
with locally persistent nasopharyngeal carcinoma (NPC).
Methods: Thirty-two patients with locally persistent NPC after full dose of IMRT were evaluated retrospectively.
3D-image-guided HDR-BT treatment plan was performed on a 3D treatment planning system (PLATO BPS 14.2).
The median dose of 16 Gy was delivered to the 100% isodose line of the Gross Tumor Volume.
Results: The whole procedure was well tolerated under local anesthesia. The actuarial 5-y local control rate for
3D-image-guided HDR-BT was 93.8%, patients with early-T stage at initial diagnosis had 100% local control rate.
The 5-y actuarial progression-free survival and distant metastasis-free survival rate were 78.1%, 87.5%. One patient
developed and died of lung metastases. The 5-y actuarial overall survival rate was 96.9%.
Conclusions: Our results showed that 3D-image-guided HDR-BT would provide excellent local control as a
salvage therapeutic modality to IMRT for patients with locally persistent disease at initial diagnosis of early-T
stage NPC.
Keywords: Nasopharyngeal carcinoma, Intensity-modulated radiotherapy, Persistent disease, 3D-image-guided
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Nasopharyngeal carcinoma (NPC) is a radiosensitive
disease, and radiotherapy is the standard therapy for
non-disseminated NPC. A growing data showed that
improvement in NPC patients treated with intensity-
modulated radiotherapy (IMRT) was demonstrated in
achieving excellent local tumor control, especially in the
locally early-T stage patients with the least toxicity [1-4].
However, local persistence of disease remains a major
hindrance to successful treatment, and the locally
persistent NPC patient carries a risk of local recurrence if
the salvaging treatment is not given, locally persistent
disease was defined as relapsed tumor within 6 months of* Correspondence: drcaoxinping@126.com
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reproduction in any medium, provided the orcompletion of primary radiotherapy, and local recurrence
was failure beyond 6 months [5,6]. Kwong et al. [7]
showed their experience in the patterns of failure in
NPC patients after the completion of radiotherapy was
associated with an increased risk of local failure. Among
803 NPC patients, fifty-five (6.8%) showed persistent
disease and positive biopsies at 12 weeks post-
radiotherapy with only 40% of 5-year local control rate.
Likewise, Sze et al. and Yan et al. also showed that the
local persistence of NPC post therapy was associated
with an increased risk of local recurrence [8,9]. Therefore,
aggressive and effective salvage treatment for locally
persistent NPC is very important [10-13].
Various salvage treatment techniques have reportedly
been effective for locally persistent NPC, including surgical
nasopharyngectomy [14], brachytherapy [5], stereotactic
radiosurgery [15,16], and three-dimensional conformal
radiotherapy (3D-CRT) [17]. In our cancer center, routine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Customer-designed applicator for nasopharyngeal
brachytherapy was placed at treatment positions near the
persistent tumor under local anesthesia with fiberoptic
endoscopic guidance via the inferior meatus.
Ren et al. Radiation Oncology 2013, 8:165 Page 2 of 9
http://www.ro-journal.com/content/8/1/1652D brachytherapy was given for salvaging NPC with
biopsy-proven persistence before May 2005. Since then,
3D-image-guided high-dose-rate intracavitary brachytherapy
(3D-image-guided HDR-BT) was used instead for this
group of patients. 3D-image-guided HDR-BT is a new
treatment method that uses PLATO BPS workstation
(Nucletron B.V., Veenendal, the Netherlands). 3D-brachy-
therapy treatment planning is based on a set of CT, MR or
UltraSound (US) images. Empty catheters are placed within
the patient via meatus. Once the catheters are in place,
a set of CT images is taken and the catheters are
reconstructed on these images. Following the catheter
reconstruction, the source positions and dwell times are
planned and the plan is optimized [18-22]. This planning
strategy enables us to build up the real time isodose distri-
bution in all CT slices to increase accuracy of delivery of
the prescribed dose. Previous studies have reported
that external beam radiotherapy (ERT) combined with
3D-HDR-ICBT treatment was an effective treatment
modality in cervical cancer [23,24], breast cancer [25],
and prostate cancer patients [26], and so on. In 2010,
Johanne et al. [27] compared the dose conformity of
CT-based 3D high-dose-rate brachytherapy (3D-HDR-BT)
and IMRT to deliver a boost to the prostate after external
beam radiotherapy, they reported that CT-based 3D
HDR-BT produced a more conformal plan for the boost
to the prostate than IMRT.
Therefore, we conducted a retrospective study to evaluate
the therapeutic benefit of 3D-image-guided HDR-BT
modality for salvage treatment of locally persistent disease
after intensity-modulated radiotherapy (IMRT) in patients
with nasopharyngeal carcinoma (NPC).Figure 1 The customer-designed applicator for nasopharyngeal
intracavitary brachytherapy.Methods
Selection criteria for 3D-image-guided HDR-BT
This retrospective analysis recruited 32 NPC patients
with locally persistence. The study was approved by the
institutional reviewed board at Sun Yat-sen University
Cancer Center. Locally persistent disease was defined as
relapsed tumor within 6 months of completion of primary
radiotherapy, and local recurrence was failure beyond 6Figure 3 Four customer designed applicators for
nasopharyngeal brachytherapy were immobilized.
Figure 4 Patient was immobilized in the supine position with a
thermoplastic mask.
Figure 5 Axial computed tomography (CT) image showed the applicato
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have local persistence, each patient underwent physical
examination, fiber-optic nasopharyngoscopy, chest X-ray,
abdominal ultrasonography, and MRI/CT scan of the base
of the skull, nasopharynx, and neck. Additional tests to
evaluate the extent of disease included liver function tests,
alkaline phosphatase, chest x-ray, liver or bone scans when
indicated. 3D-image-guided HDR-BT was given when the
following criteria were satisfied: 1). the persistent disease
was biopsy-proven; 2). persistent tumors either confined
to the nasopharynx or involving the upper choana with 5
mm nasal extension.
Treatment methods and response assessment
The patients with locally persistence were treated
with 3D-image-guided HDR-BT using a 192Ir source
(microSelectron; Nucletron) when the selection criteria
were satisfied at a median of 12 weeks after IMRT. The
3D-image-guided HDR intracavitary brachytherapy
was delivered using a high-dose-rate (HDR) afterloading
machine (microSelectron, Nucletron, Veenendaal, the
Netherlands). All patients were treated under localrs in situ for brachytherapy intracavitary with different isodose lines.
Table 1 Characteristics of 32 NPC patients with locally
persistent after IMRT
Characteristic N %
Age (years) Median 44
Range 29 ~68
Gender Male 25 78.1
Female 7 21.9
Histology WHO type I 1 3.1
WHO type II 6 18.8
WHO type III 25 78.1
T stage T1 6 18.8
T2 12 37.5
T3 12 37.5
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inferior meatus to the treatment positions. Patients were
immobilized in the supine position with a thermoplastic
mask. All procedures were performed by the experienced
radiation oncologist. Treatment plan was performed as
follows: 1) two to four customer designed nasopharyngeal
brachytherapy applicators (Figure 1) were placed at
treatment position under local anesthesia with fiberoptic
endoscopic guidance via the inferior meatus and the appli-
cators were then immobilized (Figures 2, 3 and 4); 2) CT
scanning using a 0.2 cm step to obtain 0.2 cm thick
slices was performed and CT images were subsequently
transferred to a 3D treatment planning system (PLATO
PBS 14.2); 3) For all patients, gross tumor volume (GTV),
clinical target volume(CTV) were assessed. To delineate
these target volumes, MR images that were obtained were
used as the reference. The GTV was determined by a
radiation oncologist as the macroscopic extent of the
persistent disease area. The CTV included the persistent
disease area & a margin (0.5 cm) around the GTV; 4)
following all target volumes defined and the applicators
reconstruction, The PLATO PBS was used to calculate the
dosimetry for a HDR 192Ir stepping source. The distance
between each source step was 2.5 mm; 5) the dose
optimization was done step by step manually. This planning
strategy enables us to build up the real time isodose distri-
bution in all CT slices to increase accurate delivery of the
prescribed dose (Figure 5). Conformity index (CI=VRI/TV,
where VRI= reference isodose volume and TV= target
volume) are calculated [29]. After approval of the plan, the
treatment was delivered to the patients accordingly.
Treatment responses for all patients were evaluated
according to the WHO response criteria [30]. Confirmation
of response was assessed by nasopharyngoscopy, biopsy
and MRI scans 12 weeks after the completion of the
3D-image-guided HDR-BT treatment. All acute and late
radiotherapy toxicity was graded according to the criteria
of the Radiation Therapy Oncology Group (RTOG) of the
European Organization for Research and Treatment of
Cancer (EORTC) [31].T4 2 6.2








Concurrent chemo-radiotherapy Received 6 18.8
Not received 26 81.2
NPC: Nasopharyngeal Carcinoma; IMRT: Intensity-modulated Radiotherapy;
WHO: World Health Organization; AJCC: the American Joint Committee on
Cancer staging 7th edition (2011).Follow-up and statistical analyses
All patients were seen and carefully evaluated by an expe-
rienced radiation oncologist. The duration of follow-up
was calculated from the first day of brachytherapy to
either the day of death or the day of last examination.
Survival rates were calculated based on the date of
diagnosis of local persistence. The primary endpoint of
this study (interval to the first defining event) were assessed:
local failure free survival (LFFS), disease-free survival rate
(DFS), distant metastasis-free survival rate (DMFS), and
overall survival (OS). Actuarial survival was calculated
according to the method of Kaplan-Meier [32].Results
Patient populations and characteristics
Between May 2005 and December 2009, 32 consecutive
patients with locally persistence received 3D-image-guided
HDR-BT as salvage treatment 12 weeks after a full course
of IMRT in our institute. Evaluation of treatment response
and toxicity was made in single individual patient. The
demographic details are shown in Table 1. The male/
female ratio was 3.5:1 with 25 males and 7 females, and
the median age was 44 y (range, 29~68 y). Histological
examination showed that 96.9% of the patients had
World Health Organization (WHO) Type II or III disease,
3.1% had WHO Type I disease.
Response to radiotherapy and survival
The 3D-image-guided HDR-BT was given as salvage
treatment at median 12 weeks (range 10~16 weeks) after
the primary treatment. Figure 5 shows the conformality
of the dose distribution, the dosimetry planning was
done based on CT images, the CTV was covered 100%
of the prescription dose of 12 to 20 Gy (mean 16 Gy/4
fractions). All 32 patients achieved complete response
(CR = 100%). Median time to complete regression was
1.0 months (range, 0.5~1.8 months).
Figure 6 Actuarial local failure-free survival (LFFS) curves in patients with locally persistent NPC disease treated with the 3D-image-guided
HDR-BT after IMRT.
Table 2 Failure patterns in NPC patients with locally persistent disease






for relapse Time to relapse (mo) Relapse site
























7 F/42 T2 rT2a IMRT 68 Gy
3D-HDR-ICBT
17 Lung(29 months died)20 Gy
AJCC: American Joint Committee on Cancer staging system (2002); Pt. No.:patient number; F/M: female, male; IMRT: Intensity-modulated Radiotherapy; Chemo-IMRT:
concurrent IMRT and chemotherapy; 3D-HDR-ICBT: Three-Dimensional CT-based high-Dose-Rate Intracavitary Brachytherapy. Time to relapse (mo): After second
treatment(3D-HDR-ICBT) for relapse, the time, patients developed local recurrence and/or distant metastasis, is defined as Time to relapse (mo).
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oped local recurrence and/or distant metastasis (Table 2).
Two patients developed locoregional failure, the one
patient (T3N1, WHO III) had recurrence in parapharyngeal
space at 14 months after completing treatment, and the
other one (T4N2, WHO III) in the skull base at 16
months, respectively, they were successfully retreated. The
5-y actuarial LFFS rate was 93.8% shown in Figure 6.
Further study showed that the patients with local persist-
ence at initial diagnosis of early-T stage NPC had excellent
5-y LFFS rate (100%) comparing to those with advanced T
stage NPC.
Four patients developed distant metastases: bone
metastasis in two patients at 27, 34 months respect-
ively; liver metastasis in one patient at 24 months and
lung metastases in one who died at 29 months after
3D-image-guided HDR-BT treatment. As shown in
Figure 7. The actuarial 5-y DMFS rate after treatment
was 87.5%.
One patient developed neck node recurrence at 19
months after 3D-image-guided HDR-BT treatment. The
5-y actuarial DFS rate was 78.1%, and the PFS curve is
shown in Figure 8. In the present study, one patient
died of lung metastasis at 29 months after 3D-
image-guided HDR-BT treatment. The 5-y actuarial OS
rate was 96.9%.Figure 7 5-y actuarial distant metastasis-free survival (DMFS) curves i
and 3D-image-guided HDR-BT.Side effects and complications
The whole procedure of 3D-image-guided HDR-BT was
generally well tolerated under local anesthesia. On follow-
up examination, toxicity was mainly grade 1 or grade 2.
The most common radiation-related complication was
grade I or II xerostomia. No patient experienced beyond
grade II xerostomia. Thirteen patients experienced grade
I/II mucositis, which recovered to normal except a small
white scar corresponding to the brachytherapy applicator
position. Nasopharyngeal middle ulceration was observed
in two patients with foul-smelling crust, one patient devel-
oped synechiae of the nasal mucosal linings at 23 months
after treatment. The maximum oral aperture was measured
in all 32 patients to assess temporomandibular joint
dysfunction, and the mean pre- and post-treatment
aperture was 4.5 cm and 4.0 cm, respectively. The difference
between pre- and post-treatment aperture was not statisti-
cally significant. Total hearing loss, neck fibrosis limiting
movement, and neurological complications (temporal lobe
necrosis and cranial nerve palsy) were not observed in this
study.
Discussion
Recently, the use of 3D treatment planning system has
increased in most radiotherapy facilities. This method
allows for a better assessment of GTV and the definitionn patients with locally persistent NPC disease treated with IMRT
Figure 8 5-y actuarial disease-free survival (DFS) curves in patients with locally persistent NPC disease treated with the 3D-image-guided
HDR-BT after IMRT.
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proaches. A 100% isodose line was selected to cover the
entire target as optimally as possible, then manual
optimization on each CT slice was done interactively by
dragging the 100% isodose line to cover the target volume
as conformally as possible in this study. Our experience
has shown that this CT-based-3D planning approach
improved target volume delineation and optimal isodose
coverage, and is more accurate and much easier than the
conventional orthogonal film dosimetry.
In the current study, we treated 32 consecutive non-
metastatic NPC patients with local persistence disease
using 3D-image-guided HDR-BT after IMRT. The whole
procedure was well tolerated under local anesthesia. The
results showed the 3D-image-guided HDR-BT was an
effective treatment technique for local persistence, the
actuarial 5-y LFFS rate was 93.8% with minimal toxicity.
On subgroup analysis, the corresponding 5-y LFFS rates
for T1, T2, T3, T4 at initial diagnosis were 100%, 100%,
91.7%, 50% respectively. The flexible customer designed
applicators can be easily placed close to the nasopharyngeal
mucosa resulting in a higher dose to the persistent lesion.
With higher mucosal dose delivered by this technique, the
benefit was gained in improving the local control of patient
treated with this technique. This treatment results support
our hypothesis that an adequate Salvage treatment tothe locally persistence could compensate for primary
treatment. In our study, 2 patients (T3 and T4 one each)
with an initial complete response developed locoregional
failure (one in parapharyngeal space and one in skull base)
as assessed by nasopharyngoscopy, biopsy and MRI scans
beyond 6 months at the completion of Salvage treatment.
For advanced T stage NPC at initial diagnosis, the locally
persistence may not be confined to the nasopharynx after
IMRT. Due to its dosimetric limitations, 3D-HDR-BT
therapy seemed to be not enough for patients with persistent
disease beyond the area of nasopharynx.
Five patients developed relapse in other sites, one in the
neck; the other 4 distant metastasis including one in the
liver; 1 in the lung and 2 in the bone. 3D-image-guided
CT-based HDR-BT did not improve the distant control
rates as a salvage treatment. These results concurred with
a previous study by Leibel SA et al. [33], which showed
that nasopharynx tumors have a higher probability of
micrometastatic dissemination at initial diagnosis, and
concluded that the effect of local tumor control on survival
cannot be determined without more effective methods
to treat disseminated disease. Chang JT et al. [34] used
18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) and found that 11% of distant metastases in
NPC patients were not discovered using the conventional
staging workup (CWU). Based on this finding, they
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should be more accurate and sensitive than CWU. Due to
its cost and availability, FDG-PET was not performed
for each single patient in our study. Therefore, it was
uncertain whether improved local tumor control by
3D-HDR-ICBT was associated with improved distant
tumor control.
Due to its rapid dose fall-off, brachytherapy with Ir-192
to the locally persistent NPC post primary IMRT can
deliver a high radiation dose to the target volume while
sparing parotid glands and other vital structures, achieving
higher local tumor control rate with relatively lower compli-
cations compared to external beam boost. The xerostomia
syndrome was commonly seen as a long-term side effect
in NPC patients when treated with primary radiotherapy.
Our data showed patients with locally persistent NPC
lesion experienced mild xerostomia when 3D-image-guided
CT-based HDR-BT was used as salvage treatment to
IMRT. Three patients experienced Grade-II mucositis
could be ascribed to the high dose to the nasopharyngeal
mucosa. During the long-term follow-up, the only compli-
cation related to brachytherapy was synechiae of the nasal
mucosal linings in one patients, which can be treated
easily by surgery, or adjust the loading pattern during the
course of placing applicators to 3D-HDR BT.
At present, the optional gap time for salvage of locally
persistent NPC patients after the completion of primary
radiotherapy is still an issue. In this respective analysis,
the mean gap period was 12 weeks. Zheng et al. [17]
reported, the median of their gap period is also 12
weeks. Kwong et al. [7] recommended a confirmatory
biopsy at 10 weeks before first salvage treatment. They
analyzed the time course of histologic remission after
radiotherapy in 803 NPC patients. Their results showed
6.9% of the total patients had residual disease at week 12,
16.3% had spontaneous remission observed in repeated
biopsy after initial positive histologic proven, defined as
delayed histologic remission; 76.8% had negative histologic
features within 12 weeks after the completion of RT,
defined as early histologic remission. They found that the
delayed histologic remission is not a poor prognostic
factor and the salvage treatment might be unnecessary.
According to their study, some patients might have
delayed histologic remission and the additional salvage
treatment might be unnecessary in our series. In contrast,
Withers et al. [35] revealed evidence of accelerated tumor
regrowth in analysis nearly 500 oropharyngeal cancer
patients with extensions of treatment from 5 to 8 weeks, a
dose increment of about 0.6 Gy per day was required to
compensate for tumor repopulation. Considering tumor
repopulation between the completion of the first course
radiotherapy and the salvage treatment, a shorter gap
period could achieve higher local control. In our current
series, the overall 5-y actuarial LFFS rate was 93.8%, andthe excellent LFFS rate was also reported by Zheng et al.
[17] 100%, 94.12%, 84.38%, 83.92% for stage T1,T2,T3,T4
disease using 3D-CRT salvage treatment at the short gap
time period. Those results showed that early intervention
for persistent NPC patients required a low salvaging
radiation dose, obtained an excellent local tumor control
with low rate of complications.
In conclusion, 3D-image-guided CT-based HDR-BT
achieved excellent local tumor control rate as salvage
treatment to primary IMRT for patients with locally
persistent NPC disease, especially for those with T1-2
disease at the initial diagnosis. Xerostomia syndrome
and other toxicities associated with this approach have
decreased. Despite high locoregional control, distant
metastasis remains main obstacle to the successful treat-
ment for this group of patients; more effective therapy is
warranted to improve the outcome.
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